An agent-based model of prostate Cancer bone metastasis progression and response to Radium223

BACKGROUND: Bone metastasis is the most frequent complication in prostate cancer patients and associated outcome remains fatal. Radium223 (Rad223), a bone targeting radioisotope improves overall survival in patients (3.6 months vs. placebo). However, clinical response is often followed by relapse an...

Descripción completa

Detalles Bibliográficos
Autores principales: Casarin, Stefano, Dondossola, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325060/
https://www.ncbi.nlm.nih.gov/pubmed/32600282
http://dx.doi.org/10.1186/s12885-020-07084-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325060/
https://www.ncbi.nlm.nih.gov/pubmed/32600282
http://dx.doi.org/10.1186/s12885-020-07084-w

Ejemplares similares